All News
Rheumatology Salaries Remain Low
The annual Medscape Physician Compensation report was published and shows only modest salary gains for most specialists.
Read Article
Top 20 Best Rheumatology Hospitals - 2025
U.S. News & World Report has published its Best Hospitals for 2025, listing the best among many specialties, including rheumatology. Each year, U.S. News ranks hospitals in 15 specialties and for the 8th year in a row, Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report.
Read Article
HCQ Preserves Renal Function in Lupus Nephritis
d
MedPage Today
Lupus nephritis patients on long-term therapy with hydroxychloroquine showed significantly less decline in renal function, compared with patients treated otherwise, a 10-year retrospective study indicated.
Read Article
Factors Affecting Biologic Use in Rheumatoid Arthritis
A San Francisco Rheumatoid Arthritis Panel cohort survey between 1999–2011, showed numerous sociodemographic, disease, and health characteristics that influenced the initiation of treatment with biologic agents for rheumatoid arthritis (RA).
Factors Affecting Biologic Use in Rheumatoid Arthritis
A San Francisco Rheumatoid Arthritis Panel cohort survey between 1999–2011, showed numerous sociodemographic, disease, and health characteristics that influenced the initiation of treatment with biologic agents for https://t.co/azDYk6saHN
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey: Starting a new biologic agent in RA, when do you expect to see a good response? CLICK HERE>> https://t.co/NBXu4cNLVj
a.6 weeks
b.3 months
c.4 months
d.6 months
e.With adverse events
Dr. John Cush RheumNow ( View Tweet)
Cancer screening in RA - retrospective, matched cohort study of 1,614 RA vs 1,597 controls (mean 63 yrs); @ 5 yrs, RA had less cervical cancer screens (52% vs 58%) (aHR:0.83); but no decrease in screens for breast (aHR:0.98), prostate (aHR:0.99), or colorectal (aHR:1.04) CA https://t.co/NnxRnZcZwq
Dr. John Cush RheumNow ( View Tweet)
knee osteoarthritis, genicular artery embolization can provide long-lasting pain relief, improved functional outcomes, and enhanced quality of life during a 12-month period. https://t.co/sJuESpvehY
Dr. John Cush RheumNow ( View Tweet)
"FLAME" - machine learning model developed to predict SLE flares. Data from 28,433 SLE pts (2011-2022) looked at clinical & social determinants of health (SDoH) to predict 3 mo flare risk. AUROC = 0.67; SHAP analysis identified HA, OBS, & pyuria as predictors. Is this the https://t.co/6Eqqc9w2oV
Dr. John Cush RheumNow ( View Tweet)
PsA is worse in women--why? 100 PsA pts, serum study of differentially expressed proteins - 20 times more sex-specific DEPs in PsA males than females (PsA vs controls). In women leukotriene A-4; and in men IL-36, NEK7 & PIK3CA/PIK3R1 were significant predictors. https://t.co/JzI1n6Hf5G
Dr. John Cush RheumNow ( View Tweet)
CKD & Osteoporosis Rx Revisited (7.25.2025)
Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.
https://t.co/k78DRpWIJS https://t.co/aYKvIhmJN1
Dr. John Cush RheumNow ( View Tweet)
Heart Attack No Longer the Leading Cause of Death in America . Journal of AHA reports that heart disease mortality in the United States dropped by 66 percent over the past five decades, driven largely by a dramatic decline in fatal heart attacks. https://t.co/whMQSMozVv https://t.co/ik6uydmspF
Dr. John Cush RheumNow ( View Tweet)
Systemic immune-inflammation index (SII), as a potential biomarker -- computed as platelet count × neutrophil count/lymphocyte count. SII has been shown to be useful in RA, PsA, SpA, SLE and vasculitis, reflecting disease activity, drug responses & supplements ESR & CRP levels https://t.co/LuFaYbWiWN
Dr. John Cush RheumNow ( View Tweet)
Review of risankizumab efficacy & safety included 545 psoriasis pts showing Mean PASI decreased from 14 to 0.5 at 208Wk. PASI100 achieved in 33% and 74% at 16Wk & 208Wk. Bio-naïve responded faster bio-experienced pts - only 5 pts D/C for adverse events https://t.co/VklLWpD0SF https://t.co/zZfuiFijd4
Links:
Dr. John Cush RheumNow ( View Tweet)
MTX or TNFi use in elderly #RA pts w/in a year of Dx of melanoma was not associated with increased mortality. This included melanoma in situ (48%), localized (47%) and regional (5%) melanoma. Steroid use however was assoc w/ reduced survival. https://t.co/QOXfEf51S1 https://t.co/6BPtEV6sOU
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA is evaluating the safety of Vyvgart Hytrulo, ((efgartigimod) used to treat AChR Ab positive generalized myasthenia gravis (gMG). But in clinical trials there are reports of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)” https://t.co/6GBwIJ4ig4
Dr. John Cush RheumNow ( View Tweet)
Osteoporosis Drug May Lower Osteoarthritis Risk
A target trial emulation study using administrative claims suggests that romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis. https://t.co/fWWw2t2jzR
Dr. John Cush RheumNow ( View Tweet)
PMR & GCA not assoc w/ increased mortality, Norway study of 274 isolated PMR (mean age 72 yrs) & 63 GCA (age 72 yrs) pts. After mean F/U 13.7 yrs 96% were deceased. Standardized mortality ratio was Not incr for PMR (0.97)or GCA (1.10), but men w/ PMR had , lower all-cause https://t.co/03lNpQiVYZ
Dr. John Cush RheumNow ( View Tweet)
"Let the young know they will never find a more interesting, more instructive book than the patient himself." – Giorgio Baglivi
Dr. John Cush RheumNow ( View Tweet)
Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors
Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer. https://t.co/i3FMOCbyNg
Dr. John Cush RheumNow ( View Tweet)
